Peddock Capital Advisors’s AbbVie ABBV Stock Holding History

Peddock Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$620K	Sell	2,850 -2	-0.1%	-$444	0.14%	101
2025 Q4	$652K	Buy	2,852 +67	+2%	+$15.3K	0.14%	94
2025 Q3	$645K	Buy	2,785 +23	+0.8%	+$4.68K	0.14%	95
2025 Q2	$513K	Sell	2,762 -10	-0.4%	-$1.86K	0.12%	100
2025 Q1	$581K	Buy	2,772 +35	+1%	+$6.8K	0.15%	98
2024 Q4	$486K	Sell	2,737 -1,296	-32%	-$238K	0.12%	103
2024 Q3	$796K	Hold	4,033	–	–	0.19%	89
2024 Q2	$692K	Buy	4,033 +33	+0.8%	+$5.47K	0.18%	89
2024 Q1	$728K	Sell	4,000 -4	-0.1%	-$689	0.19%	91
2023 Q4	$620K	Buy	4,004 +35	+0.9%	+$5.1K	0.19%	90
2023 Q3	$592K	Buy	3,969 +2	+0.1%	+$294	0.2%	88
2023 Q2	$535K	Buy	3,967 +141	+4%	+$20.7K	0.18%	94
2023 Q1	$610K	Buy	3,826 +347	+10%	+$53.1K	0.21%	86
2022 Q4	$562K	Sell	3,479 -630	-15%	-$96.6K	0.22%	88
2022 Q3	$551K	Buy	4,109 +76	+2%	+$10.9K	0.23%	96
2022 Q2	$618K	Sell	4,033 -56	-1%	-$8.56K	0.24%	91
2022 Q1	$663K	Buy	4,089 +1	+0%	+$145	0.21%	101
2021 Q4	$554K	Sell	4,088 -199	-5%	-$23.5K	0.18%	100
2021 Q3	$462K	Sell	4,287 -991	-19%	-$113K	0.16%	102
2021 Q2	$614K	Sell	5,278 -5	-0.1%	-$563	0.21%	97
2021 Q1	$572K	Buy	5,283 +201	+4%	+$21.5K	0.22%	97
2020 Q4	$545K	Hold	5,082	–	–	0.28%	73
2020 Q3	$445K	Sell	5,082 -128	-2%	-$12.1K	0.27%	77
2020 Q2	$511K	Buy	5,210 +1,860	+56%	+$164K	0.32%	65
2020 Q1	$255K	Hold	3,350	–	–	0.19%	81
2019 Q4	$297K	Hold	3,350	–	–	0.15%	90
2019 Q3	$254K	Hold	3,350	–	–	0.14%	97
2019 Q2	$244K	Hold	3,350	–	–	0.13%	102
2019 Q1	$270K	Hold	3,350	–	–	0.15%	92
2018 Q4	$309K	Hold	3,350	–	–	0.18%	81
2018 Q3	$317K	Hold	3,350	–	–	0.15%	94
2018 Q2	$310K	Hold	3,350	–	–	0.16%	97
2018 Q1	$317K	Hold	3,350	–	–	0.17%	93
2017 Q4	$324K	Hold	3,350	–	–	0.16%	92
2017 Q3	$298K	Hold	3,350	–	–	0.15%	94
2017 Q2	$243K	Hold	3,350	–	–	0.13%	103
2017 Q1	$218K	Hold	3,350	–	–	0.13%	99
2016 Q4	$210K	Sell	3,350 -503	-13%	-$30.7K	0.12%	96
2016 Q3	$243K	Hold	3,853	–	–	0.15%	90
2016 Q2	$239K	Buy	+3,853	New	+$235K	0.15%	85
2016 Q1	–	Sell	-3,368	Closed	-$200K	–	89
2015 Q4	$200K	Buy	+3,368	New	+$194K	0.15%	91
2015 Q3	–	Sell	-3,350	Closed	-$225K	–	99
2015 Q2	$225K	Buy	+3,350	New	+$219K	0.18%	101
2015 Q1	–	Sell	-3,350	Closed	-$219K	–	100
2014 Q4	$219K	Buy	+3,350	New	+$211K	0.18%	96

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Peddock Capital Advisors's ABBV Position: Q1 2026 in Review

Peddock Capital Advisors reduced its AbbVie (ABBV) stake by 0.07% in Q1 2026, selling an estimated $444 and leaving 2,850 shares worth $620K. The position accounts for 0.14% of the portfolio, ranked #101.

Peddock Capital Advisors first reported a position in ABBV in Q4 2014 and has held it in 43 quarters since. The position peaked at $796K in Q3 2024. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Peddock Capital Advisors held 2,850 shares of AbbVie worth $620K as of Q1 2026.
Peddock Capital Advisors sold 2 AbbVie shares in Q1 2026, an estimated $444.
AbbVie made up 0.14% of Peddock Capital Advisors's portfolio in Q1 2026, its #101 holding.
Peddock Capital Advisors first reported a position in AbbVie in Q4 2014 and has held it in 43 quarters since.
Peddock Capital Advisors's AbbVie position peaked at $796K in Q3 2024.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Peddock Capital Advisors's 13F filing for Q1 2026, filed 15 Apr 2026.